Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Hypertension, Vascular Diseases, Cardiov...
Phase NA
Enrollment 130
Locations 21 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Symplicity Spyral™ multi-electrode renal denervation system — After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.

Primary Outcomes

  • Procedure time (Procedure)
  • Office Systolic Blood Pressure Change (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-22
Completion: 2030-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medtronic Vascular
Principal Investigators:
  • David Lee, MD (PRINCIPAL_INVESTIGATOR) - Stanford University
  • Konstantinos Tsioufis, Prof Dr (PRINCIPAL_INVESTIGATOR) - Hippokration General Hospital of Athens
Contact Information
Study Contact:
Adela Martinez Sanchez
+31 43 356 6566
adela.h.martinezsanchez@medtronic.com
Carly Loudoun
+31 43 356 6566
rs.spyralaffirm@medtronic.com
Tony Walton, MD
The Alfred Hospital
Interventions
  • Device: Symplicity Spyral™ multi-electrode renal denervation system — After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
Study Locations (21 sites)
The Alfred Hospital, Melbourne, Australia
Royal Perth Hospital, Perth, Australia
Ziekenhuis Oost Limburg, Genk, Limburg 3600 Belgium
CHC MontLégia, Liège, Liège 4000 Belgium
Algemeen Stedelijk Ziekenhuis - Campus Aalst, Aalst, Belgium
AZ Sint Jan Brugge-Oostende av, Bruges, 8000 Belgium
Universitair Ziekenhuis Gent, Ghent, 9000 Belgium
Universitat des Saarlandes, Homburg, Saarland 66123 Germany
Sana Kliniken Lübeck GmbH, Lübeck, Schleswig-Holstein 23560 Germany
Universitätsklinikum Erlangen, Erlangen, Germany
Eligibility Criteria
Inclusion Criteria: 1. Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg 2. Individual has a baseline office diastolic blood pressure ≥ 90 mmHg 3. Individual has an average systolic baseline home blood pressure ≥135 mmHg (with ≥7 days of valid pre-procedure measurements) 4. Individual has a valid 24-hour Ambulatory Blood Pressure Measurement at baseline Exclusion Criteria: 1. Individual lacks appropriate renal artery anatomy 2. Individual has undergone prior renal denervation 3. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement 4. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea 5. Individual has an estimated glomerular filtration rate (eGFR) of \<45 mL/min/1.73m2 6. Individual has one or more episode(s) of orthostatic hypotension 7. Individual is pregnant, nursing or planning to become pregnant 8. Individual has documented primary pulmonary hypertension 9. Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%
Conditions Maternal Health Care, Hypertensive Disor...
Phase NA
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Quality improvement (QI) initiative to improve uptake and utilization of Connected MOM, particularly among those with limited access to health care

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Other: Connected MOM + — Navigator support to encourage enrollment, consistent use, and postpartum follow-up in Connected MOM program

Primary Outcomes

  • Successful use of the intervention and control programs measured by enrollment aggregate (6-9 months)
  • Successful use of the intervention and control programs as determined by the systolic and diastolic blood pressure measurements (6-9 months)
  • Successful use of the intervention and control programs as determined by postpartum blood pressure measurement (6-9 months)
  • Adequacy of prenatal care (6-9 months)
  • Adverse composite maternal outcome (6-9 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-01
Completion: 2029-10
Eligibility
Age: 18 Years – 80 Years
Sex: FEMALE
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tulane University
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Ochsner Health System
Principal Investigators:
  • Emily W Harville, PhD (PRINCIPAL_INVESTIGATOR) - Tulane University Weatherhead School of Public Health
Contact Information
Study Contact:
Emily W Harville, PhD
504-988-7327
harville@tulane.edu
Sherri M Longo, MD
504-842-4151
slongo@ochsner.org
Sherri Longo, MD
504-842-4151
slongo@ochsner.org
Ochsner Health
Interventions
  • Other: Connected MOM + — Navigator support to encourage enrollment, consistent use, and postpartum follow-up in Connected MOM program
Study Locations (1 sites)
Ochsner Health, New Orleans, Louisiana 70121 United States
Eligibility Criteria
Inclusion Criteria: * Access to a smartphone * Understanding of English or Spanish in oral and written discourses * Have a participating Ochsner-employed provider * Plan to deliver at a participating Ochsner hospital * Reside in a zip code served by the participating clinics Exclusion Criteria: * Provider feels that study participation is not in patient's best interest * Does not understand English or Spanish well enough to follow recommendations * Plans to move from the study area served by the participating clinics
Conditions Subclinical hypothyroïdism, Non-Alcoholi...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

additive efficacy of physical activity program in hypthyroidism in elder females with glaucoma and fatty liver issues was not investigated

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: physical activity — hypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine and physical activity program on treadmill thrice weehly for 6 month
  • Other: usual care — hypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine only

Primary Outcomes

  • intraocular pressure (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-15
Completion: 2026-12-15
Eligibility
Age: 65 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cairo University
Principal Investigators:
  • Ali MA Ismail, lecturer (PRINCIPAL_INVESTIGATOR) - Cairo University
Contact Information
Study Contact:
Ali MA Ismail, lecturer
01005154209
ali.mohamed@pt.cu.edu.eg
fatma M Ali
01031321109
fatma1995@gmail.com
ali AM Ismail, lecturer
+201005154209
ali.mohamed@pt.cu.edu.eg
Cairo University
Interventions
  • Behavioral: physical activity — hypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine and physical activity program on treadmill thrice weehly for 6 month
  • Other: usual care — hypthyroidism elder females (n=20) with glaucoma and fatty liver issues that will recive their levothyroxine only
Study Locations (1 sites)
Cairo University, Dokki, Giza Governorate 11432 Egypt
Eligibility Criteria
Inclusion Criteria: * subclinical hypothrodism (significant form) * primary opened angle gaulcoma in both eyes with ocular hypertension in both eyes )(high-tension typed glaucoma) * fatty liver (non alcholic type) * elder females Exclusion Criteria: * respiratory issues * cardiac issues * renal issues
Conditions Resistant Hypertension
Phase PHASE2
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The management of patients with resistant arterial hypertension, who are characterized by a very high cardiovascular risk, remains a major therapeutic issue. The use of endothelin-1 (ET-1) receptor antagonists, in addition to lowering blood pressure, may also improve endothelial function in these patients. The objective of this study is to assess the vascular impact of an ET-1 receptor antagonist on vascular function and systemic and central hemodynamics in patients with resistant arterial hypertension and ensure their good renal tolerance.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Bosentan — vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
  • Drug: Placebo — Placebo

Primary Outcomes

  • assess the effect of ET-1 receptor antagonist administration during 8 weeks on endothelial function in patients with resistant hypertension. (through study completion, an average of 22 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-10-20
Completion: 2026-08
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Rouen
Contact Information
Study Contact:
Ludivine Lebourg, Dr
02 32 88 90 02
Ludivine.Lebourg@chu-rouen.fr
Chu Rouen
Ludivine Lebourg, Dr
Chu Rouen
Interventions
  • Drug: Bosentan — vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
  • Drug: Placebo — Placebo
Study Locations (1 sites)
Chu Rouen, Rouen, 76031 France
Eligibility Criteria
Inclusion Criteria: * age between 30 and 80 years old * Patients with resistant hypertension defined according to the criteria recognized by the French Society of Hypertension (SFHTA): arterial pressure greater than or equal to 140 and / 90 mm Hg under triple antihypertensive therapy at optimal dose comprising at least one diuretic pendant at less than 4 weeks. * Patients with resistant hypertension confirmed by self-measurement (≥135 / 85 mmHg on average) or by ambulatory blood pressure measurement (mean of 24h ≥130 / 80 mmHg). * Hemoglobin level ≥ 12 g / dL * For women of childbearing potential, reliable methods of contraception (as defined by the WHO-Pearl Index) should be used (hormonal contraception should not be the only contraceptive method used during bosentan treatment). * For postmenopausal women: confirmatory diagnosis (non-medically induced amenorrhea for at least 12 months and age greater than 45, before the inclusion visit) * Patient who read and understood the newsletter and signed the consent form * Patient affiliated to a social security scheme Exclusion Criteria: * Patients with hypertension * Patients with secondary arterial hypertension other than sleep apnea syndrome or chronic renal failure stage 2 or 3. * Patients with hypertension greater than or equal to 180 and / or 110mmHg * Chronic renal failure stage 4 and 5 (defined by DFG CKD-EPI \<30 ml / min / 1,73m²) * Renal transplant patient XML File Identifier: CEyMau8sPo+QFyOLD1ZEY3ZGFow= Page 11/22 * Orthostatic hypotension (decreased SBP\> 20mmHg and / or DBP\> 10mmHg occurring within 3 minutes of standing). * Contra-indication to NATISPRAY 0.30 mg / dose, oral spray solution (including nitrate hypersensitivity) in accordance with the NATISPRAY SPC: * shock, severe hypotension, * in combination with sildenafil * obstructive cardiomyopathy, * inferior court inferior myocardial infarction with right ventricular extension, except in case of evidence of left ventricular failure, * intracranial hypertension, • Contra-indication to BOSENTAN MYLAN 62.5 mg and 125 mg filmcoated tablets: * Hypersensitivity to the active substance or to any of the excipients listed in the SPC Moderate to severe hepatic insufficiency corresponding to class B or C of the Child-Pugh classification * Serum levels of liver aminotransferases, ASAT and / or ALAT\> 3 times the upper limit of normal at start of treatment (results less than 3 months old). * Association with ciclosporin A * Known allergy to cellulose * Patients treated with: tacrolimus or sirolimus, fluconazole or other CYP2C9 or CYP3A4 inhibitors, glibenclamide, rifampicin, antiretroviral drugs including lopinavir + ritonavir, warfarin, simvastatin, ketoconazole, epoprostenol, sildenafil and digoxin * Pregnant, breastfeeding woman, or woman of childbearing potential not using reliable methods of contraception (hormonal contraception should not be the only contraceptive method used during bosentan treatment) or no proven reliable effective contraception; * Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice, under tutorship or curatorship * Patient participating or having participated in the 4 weeks prior to inclusion in a clinical trial
Conditions HER2-positive Breast Cancer
Phase PHASE3
Enrollment 2306
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Although there is a certain risk of recurrence of HER2-positive small tumors, the overall prognosis is relatively good. In order to further reduce the toxicity and side effects of treatment and explore the best strategy for adjuvant therapy in patients with HER2-positive stage IA breast cancer, we designed this phase III, randomized, open-label study to evaluate the efficacy and safety of paclitaxel plus trastuzumab and capecitabine versus paclitaxel plus trastuzumab in the adjuvant treatment of patients with HER2-positive, node-negative breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Capecitabine — capecitabine (1000-1250mg/m2, orally, bid, D1-14, q3w) and trastuzumab (first dose 8mg/kg, q3w; Follow-up maintenance 6 mg/kg, q3w, subcutaneous or intravenous for 1 year)
  • Drug: Paclitaxel — paclitaxel (80mg/m2, qw, D1, 8, 15, intravenous, q3w) trastuzumab (first dose 8mg/kg, q3w; Follow-up maintenance 6mg/kg, q3w, subcutaneous or intravenous for 1 year)

Primary Outcomes

  • iDFS (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-07-08
Completion: 2030-06-10
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 2306 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Zhimin Shao, MD
+86-021-64175590
zhimingshao@yahoo.com
Zhimin Shao, M.D.
+86-021-64175590
zhimingshao@yahoo.com
Fudan University Shanghai Cancer Center Shanghai, China, 200032
Min He, M.D
+86-021-64175590
minsmiler@126.com
Fudan University Shanghai Cancer Center Shanghai, China, 200032
Interventions
  • Drug: Capecitabine — capecitabine (1000-1250mg/m2, orally, bid, D1-14, q3w) and trastuzumab (first dose 8mg/kg, q3w; Follow-up maintenance 6 mg/kg, q3w, subcutaneous or intravenous for 1 year)
  • Drug: Paclitaxel — paclitaxel (80mg/m2, qw, D1, 8, 15, intravenous, q3w) trastuzumab (first dose 8mg/kg, q3w; Follow-up maintenance 6mg/kg, q3w, subcutaneous or intravenous for 1 year)
Study Locations (1 sites)
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Females aged 18\~70; 2. The postoperative pathological stage of early breast cancer is stage IA: the longest diameter of invasive cancer is not more than 2cm and the lymph node is negative: pT1mic-T1cN0M0 (micro-invasion needs to meet multiple foci). 3. Pathological immunohistochemistry must meet the following conditions: HER-2 (3) or HER-2 (0-2) but amplified by FISH or CISH testing. 4. The maximum number of weeks (56 days) from surgery to randomization is not more than 8 weeks (56 days). 5. The function of major organs is normal, that is, the following criteria are met: (1) The criteria for routine blood examination must meet: HB ≥90 g/L (no blood transfusion within 14 days); ANC ≥1.5×109 /L; PLT ≥100×109 /L; (2) Biochemical tests must meet the following standards: TBIL ≤1.5×ULN (upper limit of normal value); ALT and AST ≤3×ULN; Serum Cr ≤1×ULN, endogenous creatinine clearance \>50 ml/min (Cockcroft-Gault formula); 6. Cardiac function: ECG was generally normal, QTc \< 470 ms, LVEF \>50%; 7. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up Exclusion Criteria: 1. Patients who have received neoadjuvant therapy, including chemotherapy, targeted, radiotherapy, or endocrine therapy; 2. History of other malignant tumors in the past, except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix; 3. metastasis of any site; 4. Pregnant or lactating women, women of childbearing age who cannot use effective contraception; 5. Patients who are also participating in other clinical trials; 6. Severe organ function (heart, lung, liver, kidney) insufficiency, LEVF \< 50% (ultrasound), severe cardiovascular and cerebrovascular diseases (such as: unstable angina, chronic heart failure, uncontrolled hypertension \>150/90mmgh, myocardial infarction or cerebrovascular accident) within 6 months before enrollment; Diabetic patients with poor glycemic control; Patients with severe hypertension; 7. Severe or uncontrolled infection; 8. Those who have a history of psychotropic drug abuse and cannot be quit or have a history of mental disorder; 9. Patients who are judged by the investigator to be unsuitable to participate in this study.
Conditions Breast Cancer Early Stage Breast Cancer ...
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

To prospectively evaluate the impact of HER2DX on the decision-making processes of the treating physicians and especially among the routine multidisciplinary tumour board, in defining type and setting of systemic therapy administration in patients with stage I-III HER2+ BC, and the degree of clinician's confidence in the treatment recommendation.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Neoadjuvant standard treatment for HER2+ — NEOADJUVANT SETTING
  • Drug: Adjuvant standard treatment for HER2+ — ADJUVANT SETTING

Primary Outcomes

  • Impact of HER2DX on the decision-making processes of the treating physicians and multidisciplinary tumour board, in patients with stage I-III HER2+ BC (from baseline to the end of treatment at 12 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-24
Completion: 2027-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Institute of Oncology
Principal Investigators:
  • Paola Zagami (PRINCIPAL_INVESTIGATOR) - Istituto Europeo di Oncologia
Contact Information
Study Contact:
Paola Zagami
00390294372437
paola.zagami@ieo.it
Carmen Criscitiello
00390294372689
carmen.criscitiello@ieo.it
Istituto Europeo di Oncologia
Interventions
  • Drug: Neoadjuvant standard treatment for HER2+ — NEOADJUVANT SETTING
  • Drug: Adjuvant standard treatment for HER2+ — ADJUVANT SETTING
Study Locations (1 sites)
Istituto Europeo di Oncologia, Milan, Italy Italy
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years of age; * Histologically confirmed HER2+ breast cancer; * Stage I-III breast cancer without evidence of distant metastases; * Being candidate to neoadjuvant/adjuvant therapy and locoregional treatment (surgery +/- radiotherapy); * Written informed consent, signed by the patient, to study-specific procedures (the consent will consist of 2 levels: level 1 specifically for patients enrolled in the primary endpoint cohort and level 2 for all patients); Exclusion Criteria: * HER2- BC; * Stage IV breast cancer; * Lack of informed consent because of patient's incapable of discernment or unwilling to participate;
Conditions Breast Carcinoma
Phase Not Applicable
Enrollment 750
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This study compares synthetic mammography to full-field digital mammography in image interpretation and performance metrics. Digital breast tomosynthesis (DBT) has previously been found to be superior in performance to standard digital mammography in both screening and diagnostic settings for the early detection and improved diagnosis of breast cancers. DBT in combination with full-field digital mammography (FFDM) reduces recall rates and increases cancer detection rates relative to FFDM alone. Synthetic mammography is a 2-dimensional reconstructed image, using the dataset derived from the DBT acquisition, without requiring additional radiation dose. Collecting information from patients' medical records may help doctors analyze the characteristics, utility, and impact of synthetic mammography to compared to FFDM.

Design

Study type: Observational Observational model: Case Control Time perspective: Retrospective

Interventions / Regimen

  • Other: Electronic Health Record Review — Review of medical records and past imaging examinations

Primary Outcomes

  • To analyze the impact of synthetic mammography (SM), as compared with full-field digital mammography (FFDM (through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-12-15
Completion: 2026-10-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 750 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Principal Investigators:
  • Ray C Mayo (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Ray C Mayo, MD
713-745-4555
rcmayo@mdanderson.org
Ray C. Mayo
713-745-4555
rcmayo@mdanderson.org
M D Anderson Cancer Center
Ray C. Mayo
M D Anderson Cancer Center
Interventions
  • Other: Electronic Health Record Review — Review of medical records and past imaging examinations
Study Locations (1 sites)
M D Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Female * Age 18 or older * Consecutive cases in breast imaging center Exclusion Criteria: * Cases demonstrate administrative or technical errors (e.g. missing views, labeling inconsistent with report, etc.)
Conditions Breast Ductal Carcinoma In Situ
Phase PHASE1
Enrollment 43
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma in situ. H2NVAC is a vaccine designed to stimulate specialized white blood cells in hopes of increasing immune response and protecting against breast cancer.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Granulocyte-Macrophage Colony-Stimulating Factor — Given intradermally
  • Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC — Given intradermally
  • Procedure: Therapeutic Conventional Surgery — Undergo standard of care surgery
  • Procedure: Echocardiography Test — Undergo ECHO
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Procedure: Biopsy Procedure — Undergo biopsy

Primary Outcomes

  • Adverse events (2 years)
  • Dose limiting toxicities (14 days post vaccination, 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2019-06-27
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 43 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Amy C. Degnim, M.D. (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Clinical Trials Referral Office
855-766-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic in Florida
Saranya Chumsri, M.D.
Mayo Clinic in Florida
Interventions
  • Biological: Granulocyte-Macrophage Colony-Stimulating Factor — Given intradermally
  • Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC — Given intradermally
  • Procedure: Therapeutic Conventional Surgery — Undergo standard of care surgery
  • Procedure: Echocardiography Test — Undergo ECHO
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
Study Locations (2 sites)
Mayo Clinic in Florida, Jacksonville, Florida 32224-9980 United States
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Patients must not have received any prior therapy for current DCIS * Note: Patients who received tamoxifen, raloxifene, aromatase inhibitor or another agent for prevention of breast cancer may be included as long as the patient has discontinued the treatment at least 2 months prior to baseline study biopsy if they chose to have this collected * Note: Concurrent use of endocrine therapy during the vaccination/preoperative period is not allowed. However, standard adjuvant endocrine therapy with tamoxifen or aromatase inhibitor after completion of vaccination and surgery is allowed * Any degree of HER2 expression as performed on the diagnostic clinical biopsy defined by immunohistochemistry +1, +2, or +3 * Histologically confirmed un-resected operable ductal carcinoma in situ with no evidence of lymph node involvement or distant metastasis * Note: suspected microinvasion or definite microinvasion (\< 0.1 mm invasion) on core biopsy is allowed * Patients will be asked to have an additional research biopsy prior to the first vaccination. This is not mandatory for participation * Patients must have evidence of at least 0.5 cm of disease extent based on mammogram, ultrasound, or magnetic resonance (MRI) imaging * Absolute neutrophil count (ANC) \>= 1500/mm\^3 (less than or equal to 28 days prior to registration) * Platelet count \>= 75,000/mm\^3 (less than or equal to 28 days prior to registration) * Hemoglobin \>= 9.0 g/dL (less than or equal to 28 days prior to registration) * Creatinine =\< 2 x upper limit of normal (ULN) (less than or equal to 28 days prior to registration) * Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase \[AST\]) =\< 2 x ULN (less than or equal to 28 days prior to registration) * Albumin \>= 3 g/dL (less than or equal to 28 days prior to registration) * Negative serum pregnancy test done =\< 7 days prior to Registration, for women of childbearing potential only * Willing to employ adequate contraception from the time of Registration through 6 months after the final vaccine cycle * Note: Adequate contraception methods include birth control pills, barrier device, intrauterine device, or abstinence * Capable of understanding the investigative nature, potential risks, and benefits of the study * Capable of providing valid informed consent * Willing to return to enrolling institution for all study visits (immunizations, blood draws, etc) * Willing to provide blood samples for correlative research purposes * Willing to receive a tetanus vaccination if subject has not had one within the past year Exclusion Criteria: * Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: * Pregnant women * Nursing women unwilling to stop breast feeding * Women of child bearing potential who are unwilling to employ adequate contraception from the time of registration through 6 months after the final vaccine cycle * Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens * Immunocompromised patients including patients known to be human immunodeficiency virus (HIV) positive or those on chronic steroids, unless physiologic replacement for adrenal or pituitary insufficiency * Note: Must be off systemic steroids greater than or equal to 90 days prior to Registration. However, topical steroids, inhalants or steroid eye drops are permitted * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Uncontrolled acute or chronic medical conditions including, but not limited to the following: * Active infection requiring antibiotics * Congestive heart failure with New York Heart Association class III or IV moderate to severe objective evidence of cardiovascular disease * Myocardial infarction or stroke less than or equal to 6 months prior to registration * Receiving any other investigational agent * Other active malignancy at time of registration or less than or equal to the last three years prior to registration. EXCEPTIONS: Non-melanoma skin cancer or carcinoma-in-situ (e.g. of cervix, prostate) * NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment (cytotoxics, monoclonal antibodies, small molecule inhibitors) for their cancer * Known history of active autoimmune disease that has required systemic treatment in the ≤ 30 days (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs) prior to pre-registration * NOTE: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. Patients with vitiligo, Graves' disease, or psoriasis not requiring systemic treatment within the past 30 days are not excluded. Patients with Celiac disease controlled with diet modification are not excluded * Any prior hypersensitivity or adverse reaction to GM-CSF * History of trastuzumab-related cardiac toxicity requiring interruption or discontinuation of therapy, even if left ventricular ejection fraction (LVEF) fully recovered * Baseline LVEF with a value below 55% * Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment * History of myocardial infarction =\< 168 days (6 months) prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life threatening ventricular arrhythmias * History of ipsilateral radiation to the current affected breast with DCIS
Conditions Breast Cancer
Phase PHASE2
Enrollment 27
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant stereotactic body radiotherapy (SBRT) followed by nab-paclitaxel combined with toripalimab in patients with previously untreated HR+/HER2-negative breast cancer. Eligible patients include those with stage IIB-IIIC disease (cT3N0, cT2-4N1-3 or cT1N2-3) or stage IIA disease (cT2N0 or cT1N1) with at least two of the following high-risk factors: histologic grade 3, Ki-67 ≥50% or premenopausal with age \<50 years. A total of 27 enrolled patients will be assigned to receive the combination therapy. The primary question it aims to answer is whether this combination of radiotherapy, de-escalated chemotherapy, and immunotherapy can improve the total pathologic complete response (tpCR) rate (defined as ypT0/Tis ypN0).

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Stereotactic Body Radiation Therapy (SBRT) — The prescribed dose of radiation is 24 Gy delivered in 3 fractions (8 Gy/fraction) using SBRT technique. Subjects received SBRT for the primary breast cancer lesion at 8Gy/Fraction each time for 3 consecutive days, 1 week before the start of systemic therapy. The first day of radiation is C1D1.
  • Drug: Toripalimab — Toripalimab will be administered at a fixed dose of 240 mg via intravenous infusion every 3 weeks (q3w). The first dose is given on Cycle 2 Day 1 (C2D1), followed by dosing on the first day of each subsequent cycle for a total of 4 cycles. (Toripalimab×4 240mg D1 q3w)
  • Drug: Neoadjuvant Chemotherapy — Combined with Toripalimab, Nab-paclitaxel will be dosed at 125 mg/m² based on body surface area, administered by intravenous infusion weekly (Days 1, 8, 15 of each 21-day cycle) for 4 cycles.(T×4, Nab-Paclitaxel 125mg/m2,D1、D8、D15 q3w).
  • Procedure: Surgery — Surgery will be performed 2-6 weeks after completion of neoadjuvant therapy. The surgical approach will be determined by the investigator based on disease status and patient preference.
  • Drug: Adjuvant Chemotherapy — The anthracycline may be either Epirubicin (body surface area-adjusted 50 mg/m²) or Liposomal Doxorubicin (body surface area-adjusted 30 mg/m²) combined with Cyclophosphamide (body surface area-adjusted 600 mg/m²). Both drugs were administered intravenously every 3 weeks, and then the first day of each course was administered for 4 cycles. (EC×4, Epirubicin 50 mg/m² or Liposomal Doxorubicin 30 mg/m², comined with Cyclophosphamide 600 mg/m², D1, q3w)
  • Radiation: Adjuvant Radiotherapy — Conventional radiotherapy will be delivered to the breast/chest wall and regional lymph nodes (investigator-selected technique), with explicit prohibition of tumor bed boost irradiation.
  • Drug: Endocrine therapy — Investigator-selected adjuvant endocrine therapy will be deterimend according to applicable guidelines, considering menopausal status, recurrence risk, treatment history, comorbidities as well as patient preference.

Primary Outcomes

  • Total pathologic complete response (tpCR) rate according to RCB system (At definitive surgery, following completion of neoadjuvant SBRT and 4 cycles of nab-paclitaxel plus toripalimab (each cycle is 21 days), approximately 4 months from start of neoadjuvant therapy.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-06-05
Completion: 2030-12
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 27 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xijing Hospital
Contact Information
Study Contact:
JIAJUN DING
15121089323
yuki_ding1996@163.com
Ting Wang, PhD
0086-13700283101
ting_w100@126.com
Xijing Hospital Affiliated to Air Force Military Medical University
Ting Wang
0086-13700283101
ting_w100@126.com
Xijing Hospital Affiliated to Air Force Military Medical University
Interventions
  • Radiation: Stereotactic Body Radiation Therapy (SBRT) — The prescribed dose of radiation is 24 Gy delivered in 3 fractions (8 Gy/fraction) using SBRT technique. Subjects received SBRT for the primary breast cancer lesion at 8Gy/Fraction each time for 3 consecutive days, 1 week before the start of systemic therapy. The first day of radiation is C1D1.
  • Drug: Toripalimab — Toripalimab will be administered at a fixed dose of 240 mg via intravenous infusion every 3 weeks (q3w). The first dose is given on Cycle 2 Day 1 (C2D1), followed by dosing on the first day of each subsequent cycle for a total of 4 cycles. (Toripalimab×4 240mg D1 q3w)
  • Drug: Neoadjuvant Chemotherapy — Combined with Toripalimab, Nab-paclitaxel will be dosed at 125 mg/m² based on body surface area, administered by intravenous infusion weekly (Days 1, 8, 15 of each 21-day cycle) for 4 cycles.(T×4, Nab-Paclitaxel 125mg/m2,D1、D8、D15 q3w).
  • Procedure: Surgery — Surgery will be performed 2-6 weeks after completion of neoadjuvant therapy. The surgical approach will be determined by the investigator based on disease status and patient preference.
  • Drug: Adjuvant Chemotherapy — The anthracycline may be either Epirubicin (body surface area-adjusted 50 mg/m²) or Liposomal Doxorubicin (body surface area-adjusted 30 mg/m²) combined with Cyclophosphamide (body surface area-adjusted 600 mg/m²). Both drugs were administered intravenously every 3 weeks, and then the first day of each course was administered for 4 cycles. (EC×4, Epirubicin 50 mg/m² or Liposomal Doxorubicin 30 mg/m², comined with Cyclophosphamide 600 mg/m², D1, q3w)
Study Locations (2 sites)
Xijing Hospital Affiliated to Air Force Military Medical University, Xi'an, Shannxi Province 710032 China
Xijing Hospital Affiliated to Air Force Military Medical University, Xi'an, Shannxi China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged ≥18 and ≤75 years at the time of signing informed consent. 2. ECOG PS status of 0-1. 3. Histologically confirmed non-metastatic (M0) breast cancer, meeting all of the following: a) Clinical stage (per AJCC 8th edition) meeting one of the following: i. cT3N0, cT2-4N1-3, or cT1N2-3 (Stage IIB, IIIA, IIIB, or IIIC); ii. cT2N0 or cT1N1 (Stage IIA) with at least two of the following high-risk features: Histologic grade 3; Ki-67 ≥50%; Age \<50 years and premenopausal status. b) Imaging assessments within 28 days prior to enrollment including: abdominal CT or ultrasound, bone scan (ECT), chest CT, and brain MRI. 4. Histologically or pathologically confirmed invasive carcinoma, with all of the following: 1. Grade 2 or 3 (confirmed by central laboratory); 2. ER-positive (\>1% staining) and/or PR-positive (\>1% staining) by IHC; 3. HER2-negative (IHC 0/1+ or HER2/neu FISH ratio ≤1.8); 4. Ki-67 ≥15%. 5. Patient deemed eligible for radiotherapy after MDT evaluation. 6. No prior antitumor therapy within 1 month before enrollment. 7. Organ Function Requirements (within 7 days prior to enrollment): 1. Complete blood count (no transfusion or hematopoietic growth factors within 7 days): ANC ≥1.5×10⁹/L; ALC ≥0.5×10⁹/L; Platelets ≥100×10⁹/L; Hemoglobin ≥90 g/L; WBC ≥3.0×10⁹/L and ≤15×10⁹/L; 2. Blood biochemistry (no transfusion/albumin within 7 days): ALT/AST ≤2.5×ULN; ALP ≤2.5×ULN;BUN/Cr ≤1.5×ULN; Cr≥60 mL/min (Cockcroft-Gault formula); 3. Coagulation: PT/APTT ≤1.5×ULN; INR ≤1.5×ULN (if no anticoagulant therapy); 4. Urinalysis: Urine protein \<2+; if ≥2+, 24-hour urine protein must be ≤1g; 5. Thyroid function:TSH ≤1×ULN; if abnormal, normal T3/T4 levels required for eligibility. 8. Women of childbearing potential must: 1. Have a negative serum pregnancy test within 7 days before treatment; 2. Use highly effective contraception during the study and for 180 days after the last dose. 9. Voluntarily sign informed consent, demonstrate good compliance, and commit to follow-up. Exclusion Criteria: 1. Inflammatory Breast Cancer. 2. Comorbidities/Medical History: 1. Autoimmune disease: patients with any known or suspected autoimmune disease, except: hypothyroidism due to autoimmune thyroiditis managed with hormone replacement therapy only, stable type-1 diabetes with well-controlled blood glucose. 2. Cardiovascular Diseases: poorly controlled hypertension despite medication (SBP \>140 mmHg or DBP\>90 mmHg). And with the history (within 6 months prior to enrollment) of myocardial infarction, severe/unstable angina, NYHA Class ≥2 heart failure, clinically significant arrhythmias as well as symptomatic congestive heart failure. 3. Interstitial lung disease, non-infectious pneumonitis, or other uncontrolled systemic diseases (e.g., diabetes, pulmonary fibrosis, acute pneumonia); 4. Vaccination: receipt of live attenuated vaccines within 28 days prior to enrollment or planned during the study; 5. Infections: HIV/AIDS, active hepatitis(HBV-DNA ≥500 IU/mL; HCV-RNA above detection limit), or co-infection with HBV and HCV, severe infections within 4 weeks prior to enrollment (e.g., bacteremia, severe pneumonia requiring hospitalization), active infection requiring systemic antibiotics (CTCAE≥Grade 2) within 2 weeks prior to treatment, active tuberculosis within 1 year prior to enrollment; 6. Unexplained fever \>38.5°C during screening (unless deemed tumor-related by the investigator); 7. Malignancy History: other malignancies diagnosed within 5 years prior to enrollment (except adequately treated basal cell carcinoma, squamous cell skin cancer, or cervical carcinoma in situ); 8. Surgery:Major surgery within 28 days prior to enrollment (diagnostic biopsies or PICC line placement are allowed); 9. Transplant: Prior or planned allogeneic bone marrow or solid organ transplant; 10. Neurological: peripheral neuropathy ≥Grade 2; 11. Gastrointestinal: clinically significant bowel obstruction; 12. Thrombotic Events: arterial/venous thrombosis within 6 months prior to enrollment (e.g., stroke, transient ischemic attack, DVT, pulmonary embolism); 13. Bleeding Risk: hemoptysis (≥2.5 mL/day) within 2 months prior to enrollment, clinically significant bleeding within 3 months prior to enrollment (e.g. gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood≥++), and the known bleeding/thrombotic disorders (e.g., hemophilia, coagulopathy, thrombocytopenia, hypersplenism); 14. Coagulation abnormalities (INR \>1.5×ULN or APTT \>1.5×ULN), or requiring long-term anticoagulation (warfarin/heparin) or antiplatelet therapy (aspirin≥300 mg/day or clopidogrel ≥75 mg/day). 3. Treatment-Related Exclusions: 1. Prior systemic targeted therapy or immunostimulants (e.g., interferon, IL-2) within 4 weeks before treatment; 2. Known allergy to the investigational drug (recombinant humanized anti-PD-1 mAb) or its excipients. 4. Clinical Trial Participation: participation in another drug trial within 4 weeks prior to enrollment, or within 5 half-lives of the last investigational drug dose. 5. Substance Abuse: history of drug/alcohol abuse or dependency. 6. Pregnancy/Lactation: pregnant, breastfeeding, or planning pregnancy during the study. 7. Investigator' s Discretion: other conditions that may compromise subject safety or study integrity (e.g., severe lab abnormalities, social factors).
Conditions Breast Cancer, Prostate Cancer, Colorect...
Phase NA
Enrollment 300
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to find out if Meaning-Centered Psychotherapy for Latinos (MCP-L) helps reduce anxiety and depression and improves quality of life compared to cognitive behavioral therapy (CBT). Investigators also want to learn what participants and providers think about the therapy, including how the therapy is designed, outside factors, available resources, and how the people involved affect how well MCP-L works.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Meaning-Centered Psychotherapy for Latinos /MCP-L — MCP-L is a structured 7-session manualized intervention culturally adapted into Spanish for Latino participants diagnosed with advanced cancer, which utilizes a mixture of didactics, discussion and experiential exercises that focus on particular themes related to meaning and advanced cancer. It is 60-minute individual sessions delivered every week or intermittently (depending on participant preference) for up to approximately 3 months (in this time period) in the event of medical illness.

Primary Outcomes

  • Change in clinical levels of anxiety and depression for participants participating in Meaning-Centered Psychotherapy for Latinos (MCP-L) (1 month)
  • Change in clinical levels of anxiety and depression for participants participating in Meaning-Centered Psychotherapy for Latinos (MCP-L) (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-01
Completion: 2029-04-13
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Devika Jutagir, PhD (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Devika Jutagir, PhD
646-888-8361
jutagird@mskcc.org
Francesca Gany, MD, MS
646-888-8054
ganyf@mskcc.org
Devika Jutagir, PhD
646-888-8361
Memorial Sloan Kettering Cancer Center
Interventions
  • Behavioral: Meaning-Centered Psychotherapy for Latinos /MCP-L — MCP-L is a structured 7-session manualized intervention culturally adapted into Spanish for Latino participants diagnosed with advanced cancer, which utilizes a mixture of didactics, discussion and experiential exercises that focus on particular themes related to meaning and advanced cancer. It is 60-minute individual sessions delivered every week or intermittently (depending on participant preference) for up to approximately 3 months (in this time period) in the event of medical illness.
Study Locations (2 sites)
Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States
Instituto Nacional de Cancerología (INCan), Mexico City, Mexico
Eligibility Criteria
Patient Eligibility Criteria: A patient cannot be considered eligible for this study unless ALL of the following conditions are met. Participant eligibility will be determined by an initial EMR review followed by a self-report screener and suicide risk assessment. Inclusion Criteria: EMR Criteria \- Documentation of Disease * Pathologically confirmed breast, prostate, colorectal, thyroid, cervix, uteri, or lung - solid tumor cancer (either most recent or new diagnosis) * Definition of Disease \[or Measurable Disease\] * Diagnosed with stages III or IV * Prior Treatment * Receiving ambulatory care at INCan Self-Report Criteria * Age ≥ 18 years * Able to read and communicate in Spanish determined by the question: "Can you read and communicate in Spanish? Yes/No" * Professional role of administrators, clinicians (e.g., oncologists), mental health providers, supervised therapists-in-training (e.g., graduate students), or other related provider delivering the MCP-L experimental intervention * Providing care (or services) to Mexican cancer patients at INCan * Has access to internet and an electronic device * Agrees to be audio-recorded Exclusion Criteria: EMR Criteria * Prior Treatment * Received psychological or psychiatric care at INCan in the last 3 months * In the judgment of the treating physician, protocol investigators, and/or study staff, presence of cognitive impairment (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and/or study participation * Diagnosed with a serious psychiatric condition Self-Report Criteria * Received psychological or psychiatric care outside of INCan in the last 3 months * Presence of suicide risk determined by the Columbia-Suicide Severity Rating Scale * Too ill to participate determined by the question: "Do you feel too ill to participate because of communication problems, uncontrollable pain, or other symptoms that prevent you from participating?" Provider Eligibility Criteria: Inclusion Criteria Self-Report Criteria * Age ≥ 18 years * Able to read and communicate in Spanish determined by the question: "Can you read and communicate in Spanish? Yes/No" * Professional role of administrators, clinicians (e.g., oncologists), mental health providers, supervised therapists-in-training (e.g., graduate students), or other related provider delivering the MCP-L experimental intervention * Providing care (or services) to Mexican cancer patients at INCan * Has access to internet and an electronic device * Agrees to be audio-recorded
Conditions Breast Cancer, Advanced Solid Tumor
Phase PHASE1
Enrollment 86
Locations 32 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BG-75202 — Administered orally.
  • Drug: CDK4 Inhibitor — Administered orally.
  • Drug: Estrogen Receptor Antagonist — Administered by intramuscular injection.
  • Drug: Aromatase Inhibitor — Administered orally.

Primary Outcomes

  • Part 1: Number of Participants with Adverse Events (AEs) (From first dose to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately 12 months)
  • Part 1: Recommended Dose for Expansion (RDFE) (Estimated approximately 1 year)
  • Part 2: Overall Response Rate (ORR) (Up to approximately 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-12-11
Completion: 2037-01-13
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 86 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: BeOne Medicines
Principal Investigators:
  • Study Director (STUDY_DIRECTOR) - BeOne Medicines
Contact Information
Study Contact:
Study Director
877-828-5568
clinicaltrials@beonemed.com
Interventions
  • Drug: BG-75202 — Administered orally.
  • Drug: CDK4 Inhibitor — Administered orally.
  • Drug: Estrogen Receptor Antagonist — Administered by intramuscular injection.
  • Drug: Aromatase Inhibitor — Administered orally.
Study Locations (32 sites)
University of Alabama At Birmingham Hospital, Birmingham, Alabama 35294-0004 United States
Yale Cancer Center, New Haven, Connecticut 06510 United States
Washington University in St Louis, St Louis, Missouri 63110-1010 United States
Next Oncology Austin, Austin, Texas 78758 United States
The University of Texas Md Anderson Cancer Center, Houston, Texas 77030-4009 United States
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-4433 United States
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales NSW 2148 Australia
Chris Obrien Lifehouse, Camperdown, New South Wales NSW 2050 Australia
Cancer Research South Australia, Adelaide, South Australia SA 5000 Australia
Austin Health, Heidelberg, Victoria VIC 3084 Australia
Eligibility Criteria
Inclusion Criteria: * Part 1A: Participants with histologically or cytologically confirmed advanced, metastatic breast cancer and other solid tumors who have exhausted, are intolerant of all available standard of care therapies, and/or without available standard of care therapies. * Part 1B and Part 2A: Participants with advanced breast cancer with 1 to 3 prior lines of systemic therapy in the metastatic setting. Prior lines in the advanced/ metastatic setting may not exceed 2 lines of chemotherapy (inclusive of antibody-drug conjugate with cytotoxic payload). * Parts 2B and 2C: Participants with advanced breast cancer enrolled in regions where cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are not approved and/or not available as the first-line treatment and who are CDK4/6 inhibitor treatment naïve and did not receive any previous systemic treatment for advanced disease. * Participants with breast cancer must have histologically or cytologically confirmed advanced breast cancer at the time of most recent testing, based on American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. * Female participants with metastatic breast cancer must be postmenopausal or receiving ovarian function suppression treatment. * Measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. * Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Adequate organ function. Exclusion Criteria: * Prior exposure to KAT6A/B or KAT7 inhibitors/degraders. * Patients with active leptomeningeal disease or uncontrolled, untreated brain metastasis. * Participants with any malignancy ≤ 3 years before screening for the study except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively which in the opinion of the investigator is unlikely to require intervention during the study. Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Conditions Breast Cancer, Heart Failure
Phase PHASE3
Enrollment 188
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Dapagliflozin — 10 mg tablet q.d
  • Drug: Placebo — tablet matching dapagliflozin 10 mg q.d

Primary Outcomes

  • Primary efficacy composite endpoint (cancer therapeutics related cardiac dysfunction) at 12 months. (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-04-15
Completion: 2027-12-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 188 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: 4th Military Clinical Hospital with Polyclinic, Poland
Principal Investigators:
  • Waldemar Banasiak, PhD, MD (PRINCIPAL_INVESTIGATOR) - 4th Military Clinical Hospital with Polyclinic
Contact Information
Study Contact:
Bartosz Krakowiak, PhD, MD
+48 261 660 234
bkrakowiak@4wsk.pl
Bartosz Krakowiak, PhD, MD
+48 261 660 234
bkrakowiak@4wsk.pl
4th Military Clinical Hospital with Polyclinic
Rafał Matkowski, PhD, MD
Lower Silesian Centre for Oncology, Lung Diseases and Hematology
Interventions
  • Drug: Dapagliflozin — 10 mg tablet q.d
  • Drug: Placebo — tablet matching dapagliflozin 10 mg q.d
Study Locations (3 sites)
4th Military Clinical Hospital with Polyclinic, Wroclaw, Lower Silesian Voivodeship 50-981 Poland
Lower Silesian Centre for Oncology, Lung Diseases and Hematology, Wroclaw, Lower Silesian Voivodeship 53-413 Poland
Military Medical Institute, Warsaw, Masovian Voivodeship 04-141 Poland
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years and \< 80 years. * Diagnosis of invasive breast cancer \[stage I-III\] and planned anthracycline treatment within 60 days. * Signed Informed Consent to participate in the study. Exclusion Criteria: * Urinary tract infection with the need for treatment with an antibiotic 48 hours before the scheduled start of anthracycline treatment. * Recognised heart failure or symptoms which, in the opinion of the investigator may be a symptom of undiagnosed heart failure. * Left ventricular ejection fraction \< 50% at the time of the screening. * Severe valvular heart disease. * A history of clinically significant arrhythmia, including atrial fibrillation regardless of type (at discretion of the investigator). * A history of stroke. * Cardiomyopathy: congenital, post-inflammatory, toxic, infiltrative (e.g. amyloidosis, sarcoidosis, haemochromatosis), postnatal or hypertrophic. * Pulmonary hypertension. * Uncontrolled arterial pressure or systolic pressure \< 80 mmHg at screening (at the discretion of the investigator). * BMI \> 40 kg/m2. * Diagnosed type 1 or type 2 diabetes or fasting glucose ≥ 126 mg/dl or HbA1C ≥ 6,5% (48 mmol/mol). * Pregnancy or breastfeeding. * Lack of compliance to use highly effective method of birth control. * Expected or possible treatment with epirubicin or liposomal doxorubicin within 12 months. * Taking another study drug or drugs from the group of SGLT2 inhibitors up to 6 months before the screening visit. * Taking semaglutide, liraglutide and metformin during the 30 days preceding the screening visit. * eGFR \< 25 ml/min/1.73m2 according to CKD EPI. * Life expectancy \< 12 months or cancer disease stage IV according to the TNM classification. * Alanine transaminase or aspartate transaminase levels above 2.5 times the local norm. * Anemia with Hemoglobin \< 9 g/dl. * Kidney failure \> G2 (according to KDIGO classification). * Liver disorders, Child-Pugh score \> 4. * Known, active infections with HIV, HBV, HCV, tuberculosis. * Any other condition which, in the opinion of the investigator, makes it impossible to fulfill the requirements for participation in this study.